Free Newsletter
VC: Hyperion lands $40M in second round
Hyperion lands $40M in second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Hyperion Therapeutics
|
$40M
|
Sofinnova Ventures |
The funding will allow Hyperion to complete the licensing deal with Medicis Pharmaceutical Corporation, build out its management team, advance clinical trials and begin U.S. promotion of the two compounds for the treatment of UCD. |
|
Agendia
|
$34M
|
ING, Van Herk Biotech, Gilde Healthcare Partners and Global Life Science Ventures |
The company developed the MammaPrint, a prognostic DNA microarray-based in vitro diagnostic test that measures the activity of 70 genes to assess the risk of breast cancer recurrence. |
|
Presidio Pharmaceuticals
|
$26M
|
Panorama Capital |
Presidio Pharmaceuticals is focused on developing therapies for chronic viral infections. |
Be the first to comment
